Clinical implications of enzyme induction and enzyme inhibition.
about
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patientsPrediction of metabolic drug interactions involving beta-adrenoceptor blocking drugsTherapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver diseaseUrinary glucaric acid excretion in rheumatoid arthritis: influence of disease activity and disease modifying drugsExposure to toluene increases the urinary excretion of D-glucaric acidEpidemiology, outcomes research, and drug interactions.The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.Theophylline and antipyrine disposition in smoking and non-smoking epileptic subjects.Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.Enzyme induction by phenobarbitone and vitamin K1 disposition in manInduction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.Adverse drug interactions.Clinically relevant anti-epileptic drug interactions.Basic concepts in drug metabolism: Part II.Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity.The effect of fever on antipyrine metabolism in children.Carbamazepine intoxication caused by interaction with isoniazid.Addison's Disease Caused by Tuberculosis with Atypical Hyperpigmentation and Active Pulmonary Tuberculosis.Induction of drug-metabolizing enzymes by dioxin.Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activityPurification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism.Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivativeEnzyme induction and beta-adrenergic receptor blocking drugs.Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect.Effects of cimetidine on carbamazepine auto- and hetero-induction in man.Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine.Cisapride has no effect on antipyrine clearance.The effects of astemizole on antipyrine clearance.Loprazolam (RU31158)--lack of effect on hepatic microsomal enzyme activity in man.Urinary 6 beta-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases.Altered corticosteroid metabolism differentially affects pituitary corticotropin response.Carbamazepine decreases antihypertensive effect of nilvadipine.Autoinduction of rifabutin metabolism in man.Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver.Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.
P2860
Q24544077-4AB56C81-9E09-49B4-A5E1-F97D55956EEFQ28365793-DA847200-1874-4311-8A61-9A56FC78C11BQ28472958-1F1A782F-271E-46F2-B231-C6D1FA23166AQ33579086-77EB1BD1-AE10-4E29-8384-04B4B7DBEB61Q33633607-D91235E9-39E6-469E-B946-C8C566FECA53Q33656679-CB9CEF29-BA2A-497C-94D1-1AE7E0914847Q34357855-4DA7C272-A0C1-4710-8E03-FBC9F98E4A5FQ34417390-E8B415FD-07F1-47FB-A41A-7F8C88ECF297Q34417445-8E44FF9A-C3F0-4B25-A6FE-16ECF4A53BBBQ34621759-213E72DA-339D-47BD-987E-2AA17FB167B8Q35030873-088AA0F6-A4C6-4950-8F87-DBBD43C1B4DDQ35826366-341B46FE-A2D9-448B-90F7-A8A86DFD4731Q36894920-9711ED51-C526-4B21-94DC-DB45744BFBA1Q37920931-2D16B992-13BC-461B-858A-AAF600CF11C0Q39679818-B8CA4512-97ED-42CB-970B-5D1A6E5D9F5CQ39879718-D96CF973-D2E6-4A75-8D1B-951CC0F10EBDQ40319472-683BFB14-A7F2-4F76-8E3E-351A0D388FA7Q40844211-DE99315A-C0CA-4873-BA23-140A9253E6B7Q41112491-355F95CD-75FB-4AEC-88F2-9B2DE217CAA0Q41307941-AB4F3351-B16E-4D19-A85C-A0431FB780EFQ41676803-DB3F331E-F0D7-46ED-A733-927009FC841CQ41787730-76121079-33A1-482C-A60B-0F471C227342Q41814066-D500F48A-13F7-46EE-99DC-4193A248927FQ41836161-01F3FA88-6118-48C9-9C38-7259B0F06341Q41987008-69A65942-B911-4F41-BF7E-D8AD704EC99FQ42106057-2599C004-68E3-4470-9488-CC63AA26A3A0Q42531502-C845C559-8C3A-4E24-BECC-DF1BEEE97D19Q42699921-9A82D1D8-9C1F-455E-9E4F-DA3B0A1E96C4Q43042356-97DFDBB8-C2E8-4182-A4E9-2C2DEF6B3D99Q43260391-0458CE40-6991-4516-827E-98EAC08FA895Q43261938-9427EA2D-3CCC-4A9C-982E-1930B183DDB6Q43657910-D739A316-9BD7-49B9-9331-596D82E2F967Q43852630-B841CF98-0657-45DA-822D-8F5FB4418B7AQ43864968-C2BBDD26-1D40-45B4-86E2-FF361791FF41Q44667368-9395D12B-F441-448F-A3B7-AFC2BCBA9F9DQ46090429-DB0BA567-3E9F-4BAB-B141-4F59C8BFEEA6Q46624949-44F43BD5-D927-42DB-B79A-B75E8F78395AQ46891654-516D58A3-1AEA-4769-9327-BECAFBCEA8CFQ47832946-FDE4B7B7-E914-405D-B175-48EC5C05EDBCQ47896238-379371E8-0AF2-48A1-AE76-8EEF7F9ED3E5
P2860
Clinical implications of enzyme induction and enzyme inhibition.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Clinical implications of enzyme induction and enzyme inhibition.
@en
type
label
Clinical implications of enzyme induction and enzyme inhibition.
@en
prefLabel
Clinical implications of enzyme induction and enzyme inhibition.
@en
P1476
Clinical implications of enzyme induction and enzyme inhibition.
@en
P2093
A M Breckenridge
P356
10.2165/00003088-198106010-00001
P577
1981-01-01T00:00:00Z
P6179
1032519843